HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

levormeloxifene

RN refers to (trans)-isomer

Also Known As:

1-(2-(p-(trans-7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl)pyrrolidine

Networked: 12 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - levormeloxifene: 12

Experts

1.	Christiansen, C: 2 articles (03/2003 - 02/2001)
2.	Delmas, P D: 2 articles (03/2003 - 02/2001)
3.	Riis, B J: 2 articles (03/2003 - 02/2001)
4.	Stakkestad, J A: 2 articles (03/2003 - 02/2001)
5.	Draper, Michael W: 1 article (03/2008)
6.	Jaffe, Robert B: 1 article (03/2008)
7.	Krishnan, Venkatesh: 1 article (03/2008)
8.	Shelly, Wendy: 1 article (03/2008)
9.	Wong, Mayme: 1 article (03/2008)
10.	Al-Azzawi, Farook: 1 article (02/2008)

Related Diseases

1.	Postmenopausal Osteoporosis 03/28/2003 - "Levormeloxifene prevents the postmenopausal bone loss, but the lowest effective dose is unknown." 09/01/2002 - "Levormeloxifene is a selective estrogen receptor modulator that was developed for the purpose of the treatment and prevention of postmenopausal osteoporosis. " 02/01/2001 - "Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy." 01/01/2006 - "Levormeloxifene is a selective estrogen receptor modulator that was developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. "
2.	Atherosclerosis 10/01/1997 - "The present study was undertaken to investigate the effect of the L-enantiomer (levormeloxifene) and the d-enantiomer (d-ormeloxifene) on the development of atherosclerosis. " 10/01/1997 - "Like estrogen, levormeloxifene did not inhibit atherosclerosis in the endothelium-denuded site of aorta. " 10/01/1997 - "In the long-term experiment, levormeloxifene, in contrast to d-ormeloxifene, significantly reduced atherosclerosis by 50% in the undamaged arterial wall of both female and male rabbits. " 08/15/1997 - "The results for levormeloxifene suggest a common mechanism of action for estrogen and partial estrogen receptor agonists on atherogenesis."
3.	Uterine Prolapse (Vaginal Prolapse) 03/28/2003 - "In the levormeloxifene groups, a total of eight women had utero-vaginal prolapse and five women reported urinary incontinence (including worsening of a previously existing condition). " 09/01/2005 - "Levormeloxifene and idoxifene, on the contrary, were noted to increase uterine prolapse and incontinence during phase III trials that prematurely terminated. "
4.	Pelvic Organ Prolapse 12/01/2001 - "Levormeloxifene and idoxifene trials noted a higher proportion of surgery for pelvic organ prolapse in treated versus untreated women. "
5.	Osteoporosis 09/01/2002 - "This was a multicentered prospective study of healthy women aged >or=65 years with osteoporosis who were randomized to blindly receive placebo or levormeloxifene 0.5 mg or 1.25 mg daily as part of a planned 3-year osteoporosis treatment study. " 09/01/2002 - "Levormeloxifene results in multiple adverse gynecologic and other events in postmenopausal women with osteoporosis." 09/01/2002 - "Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study."

Related Drugs and Biologics

1.	Lipids
2.	idoxifene
3.	Selective Estrogen Receptor Modulators (SERM)
4.	ormeloxifene
5.	Estrogens (Estrogen)
6.	Raloxifene Hydrochloride (Evista)
7.	Benzopyrans
8.	Fulvestrant (Faslodex)
9.	bazedoxifene
10.	LY 353381 (LY353381)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Estrogen Replacement Therapy